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1. Introduction 
The complexities of neurological diseases make it difficult to develop effective methods to 
treat them. In addition, it is difficult for the drugs used in neurological diseases to reach 
target cells at a sufficient concentration due to the blood-brain barrier, which may lead to 
side-effects in other organs, even though newly developed drugs are targeted directly to the 
origin of the diseases. Nevertheless, as the field of gene delivery gradually matures, new 
ways to deliver therapies for diseases become possible, and there are reasons to believe that 
gene therapy would be an optional treatment for neurological diseases. 
There are two main classes of vectors used for gene delivery: nonviral vectors and viral 
vectors (Gardlik et al., 2005). As viral vectors display a higher efficiency and specificity than 
nonviral vectors, they have been developed as therapeutic gene transfer carriers for various 
organ systems throughout the body in which the nervous system is involved (Glorioso et al., 
2003). The four major viral vector systems used for neurological diseases are recombinant 
lentivirus (LV), adenovirus (Ad), herpes-simplex virus (HSV), and recombinant adeno-
associated virus (rAAV) (Manfredsson et al., 2010). However, the utilization of these vectors 
is limited by safety concerns because of their pathogenicity (Zhang et al., 2010). 
Foamy viruses (FVs), widespread, complex retroviruses with a large genome approximately 
12-13 kb, are syncytial viruses containing two different promoters termed IP (internal 
promoter) and P (promoter) (Löchelt et al., 1995). Due to the specific structure of the viruses 
and their innocuousness in both human and primate infections, FV vectors have potential as 
a safe and capable vehicle with a larger capacity for transgenes (Williams, 2008). It has been 
reported that FV are potentially safer than gammaretroviruses and lentiviral vectors 
(Trobridge et al., 2009). In this review, we discuss the use of FV vectors as a safe and 
efficient carrier to deliver therapeutic genes for neurological disorders and other diseases. 
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2. Characteristics of foamy virus (Figure 1) 
2.1 Construction  
FVs were first described 50 years ago and are widely distributed in the natural world (Loh 
et al., 1992). They have been isolated from several mammals, including nonhuman primates, 
cattle, cats, and horses. 
 
(1) IFP35 can interact with the bovine Tas (BTas) and arrest the replication of BFV; and Bel-1 interacts 
with -enolase, then represses the activation of LTR and IP；(2) Tas can be acetylated by p300, and 
activate the virus replication；(3) PML inhibits the binding of Tas to IP and LTR. 
Fig. 1. The genomic organization of FVs and Tas of FVs interacted with other proteins in 
cells 
Once infected by FVs, life-long latency of the infected cell is obtained (Maxine et al., 2000). 
FVs contain the largest genome and possess the most complex gene structure of all the 
retroviruses. For example, the human foamy virus (HFV, also called primate foamy virus 
(PFV)) contains LTR (long terminal repeat) sequences at the 5’and 3’ ends of its genome, and 
there are three structural genes between these two LTRs that are found in all viral genomes: 
gag, pol, and env (Saïb et al., 1995). Several ORFs (open reading frames), often two or three, 
are located between the env and the LTR at the 3’end of all sequenced FVs, which encode 
autologous transactivators, including Tas, an important transactivator (Linial, 2000). The Tas 
protein is required by both the promoter (P) in the U3 region of the 5’ LTR and another 
unique internal promoter (IP) at the end of the env gene for high-level expression (Linial, 
2000). 
2.1.1 Promoters 
2.1.1.1 LTR 
Long terminal repeats (LTRs), located at the 5' and 3' end of the viral genome, are noncoding 
regions that exist in all types of retroviruses. The LTR is required for the integration of the 
viral genome into the host genome and is related to the replication, kinetics, tissue tropism, 
and pathogenicity of the virus. A U3-R-U5 (unique 3' subregion-repeat subregion-unique 5' 
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subregion) structure forms the LTR. The LTR promoter, containing a component of the U3-
R-U5 region, is a traditional retroviral promoter. The prototypical HFV U3 region is 
approximately 777 nt and includes a TATA box, transcription regulatory signals and several 
BREs (Bel1 transactivator response elements) that are located at ~89-116 nt, ~284-327 nt, 
~348-360 nt, ~418-454 nt and ~506-559 nt, respectively (Lee et al., 1993; Verdin et al., 1995). 
As there are a number of BRE regions, Choy, Kerr et al. suggested that the Bel1 regions 
regulate gene expression by integrating with intracellular transcription factors and 
transcription initiation complexes without binding directly to BREs and act as enhancers 
that work together to make a change (Lee et al., 1993; Choy et al., 1993; Kerr et al., 1993; 
Yang et al., 1997; Löchelt et al., 1994)). The negative control region in the RU5 inhibits the 
gene expression of HFV, and the viral mRNA R-U5 forms a stable secondary structure 
(Nabel et al., 1987). There is a splice donor site (SD) 51 nt downstream of the transcription 
site of the R region, where the posttranscriptional splicing of the gag, pol, env, and bel genes 
is initiated by the 5’ LTR promoter start site (Li et al., 1999). 
2.1.1.2 IP  
All FVs possess a promoter in the U3 region of the LTR. In addition to the LTR promoter P, 
they also contain another unique internal promoter, termed IP (Löchelt et al., 1993). The 
internal promoter is located at the end of env gene. These two promoters require Tas for 
high-level expression (Löchelt et al., 1994). Compared with the LTR promoter, Tas has a 
higher affinity for the IP (Kang et al., 1998). In the early stage of viral infection, the IP 
initially regulates the expression of Tas transcription through an LTR cis-acting effect and 
the participation of as yet unknown cytokines. Next, Tas affects the IP through its self-
activating mechanism to elevate its synthesis level; when the Tas protein reaches a certain 
level, the activated LTR initiates the transcription and expression of the structural gene and 
performs transformation of gene transcription and expression from the early non-structural 
gene to the late structural gene. 
2.1.2 Structural genes 
Following the 5' LTR of FVs, there are three structural genes (gag, pol, env). The newly 
synthesized 74/78 kDa precursor protein encoded by the gag gene is located in the nuclei of 
the infected cells (Schliephake et al., 1994), and it is cleaved into the matrix, capsid, and 
nucleocapsid structural protein by the viral protease (Saïb et al., 1995). The nucleocapsid 
(NC) domain of Gag protein lacks Cys-His boxes found in all other retroviral Gag proteins, 
but its C terminus possesses three glycine-arginine motifs (GR boxes) that are required for 
RNA packaging (Stenbak et al., 2004; Yu et al., 1996; Maurer et al., 1998). The pol gene 
overlaps the gag gene, and its product does not contain any Gag protein determinant; 
however, unlike other conventional retroviruses, there is no Gag-Pol fusion protein 
synthesized in the course of viral transcription, but the underlying mechanism remains 
unknown (Stenbak et al., 2004; Yu et al., 1996). The precursor protein encoded by the env 
gene, which is approximately 130 kDa, is cleaved into the SU and TM subunits during the 
process of maturation (Saïb et al., 1995; Aguzzi, 1993). Linial et al. found that the 
extracellular virions of HFV require the Env protein for further production but that the 
formation of intracellular particles seems to be independent of the Env protein (Baldwin et 
al., 1993). Unfortunately, the role of Gag, Pol, and Env in the assembly of the FVs remains 
uncertain. 
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2.1.3 Regulatory genes 
There are several ORFs encoding accessory genes or regulatory genes that are located 
between the env and the LTR and are therefore named bel genes. These ORFs encode 
autologous transactivators, including bel-1, bel-2, bel-3 and bet.  
2.1.3.1 Tas  
The regulatory gene bel-1, which is approximately 902 bp in length, is located in the 
nucleus of expressing cells and is essential for HFV replication. FVs transactivators of 
different genera have been named differently; the simian FVs transactivator, for example, 
was termed taf. However the First International Foamy Virus Meeting determined that 
these transactivators, including Taf and Bel1, should be designated Tas (Zou et al., 1996). 
The activity of the functional IP and P of FVs depends on this transactivator. 
Transcription starts from the integration of Tas and the IP, leading to transactivation of 
the IP. However, the LTR promoter will not be activated until the level of Tas reaches a 
certain level (Linial, 2000). In view of the fact that the Tas protein plays an important role 
in the transcription and replication of FVs, it has received increasing attention and interest 
among virologists. 
The interactions between Tas and other cellular molecules are complex. For example, Tas 
can be acetylated by p300 and PCAF (Bodem et al., 2007). Recently, an interaction between 
Tas and transcriptional coactivators, such as HATs, was reported. Studies show that only 
acetylated Tas enhances viral transcription (Bodem et al., 2007). Interferon-induced 
proteins (IFPs) complete multiple functions through various interferon signals. IFP35, 
which is approximately 35 kDa, is a member of the IFP family. It interacts with the bovine 
foamy virus Tas regulatory protein, and its overexpression disturbs viral gene 
transcription and replication of the bovine foamy virus Tas protein. Furthermore, IFP35 
plays a crucial role in the interferon-induced anti-foamy virus host response (Tan et al., 
2008). First discovered by Lohman and Mayerhof in 1934 (Lohman et al., 1934), α-enolase 
was  later shown to be a highly conserved enzyme that catalyses the transformation of 2-
phosphoglyceric acid to enolphosphopyruvate in the Embden-Meyerhof-Parnas pathway 
(Wold, 1971). α-Enolase interrupts the transactivation of Tas with the promoters during 
viral transcription (Wu et al., 2009). The promyelocytic leukemia protein (PML) is a cell 
growth and tumor suppressor gene, which is expressed in the nucleus and whose 
expression is increased significantly in the response to interferon (IFN) (Wang et al., 1998). 
Regad et al. found that PML inhibits the binding of Tas to the IP and LTR by direct 
interaction with Tas (Regad et al., 2001). 
2.1.3.2 Bet   
Bet is a second IP regulating protein. Generated by the combination of the spliced mRNA 
of the Tas region and the Bel2 ORF (Linial, 2000), overexpression of Bet prevents the virus 
from infecting the host and inhibits viral integration at the initial stage of viral infection 
(Bock et al., 1998). A variant RNA can be generated by the LTR promoter, which has the 
ability to generate Bet protein fragments that, after reverse transcription, could induce the 
expression of a △Tas provirus (Saïb et al., 1993). Because of the deficiency of Tas in the 
provirus, △Tas plays a significant role in the preservation and latency of FVs, which 
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clarifies that the LTR does not initiate the synthesis of viral protein, whereas the 
expression of Bet is induced by IP (Linial, 2000). Transcription may be different in diverse 
cell types. Additionally, the combination site of Tas for the internal promoter IP is 
different from that for the LTR promoter, and the required cytokines are different. High 
expression of the virus would be suppressed under conditions in which the IP promoter 
was active in various cell types, yet cytokines, which the LTR promoter requires, exist in a 
select few cells. The transcription of integral provirus is mainly initiated by IP and will 
express Tas and Bet but virus will not. 
2.2 Replication and transcription 
As mentioned previously, FVs are a member of the spumavirus genus of the retroviridae 
family. It is believed that the replication and transcription mechanisms of various family 
members are similar (Coffin, 1990). However, Yu et al. found that although HFV possesses a 
replication pathway with features of both retroviruses and hepadnaviruses, there are also 
unique features contained in the assembly and reverse transcription pathway (Yu et al., 
1996). 
At an early stage of viral infection, Tas is expressed due to the high level of transcription of 
IP, which in turn transactivates the expression of IP and LTR, leading to the expression of 
accessory and structural genes, respectively, inducing late stage viral infection (Löchelt et 
al., 1994). The Gag-Pol fusion protein is synthesized during the transcription of other 
retroviruses. However, as discussed above, the pol gene product in foamy viruses does not 
contain any Gag protein determinant, which means there is no Gag-Pol fusion protein 
synthesized in the course of viral transcription. Therefore, unknown mechanisms exist in the 
synthesis of pol gene products. As there are two promoters present in the genome of foamy 
virus, it is presumed that IP functionally replaces the post-transcriptional regulatory protein 
of other retroviruses and thus provides a temporal pattern with stage-specific promoters 
(Mergia, 1994).  
Although FVs infection can result in a unique foam-like cytopathic effect and syncytia in cell 
cultures, they are nonpathogenic in naturally or experimentally infected animals, and the 
pathogenicity to their hosts remains unknown. However, more and more research groups 
are attracted to FVs due to the lack of pathogenicity; thus, increased attention has been 
given to the development of FVs as vectors of target gene delivery. 
3. The development of human foamy virus (HFV) (Figure 2) 
3.1 Replication-competent HFV 
The first described FVs vectors (pFOV-1, pFOV-3 and pFOV-7) were replication-
competent. Noncoding sequences in bel-2 and bel-3 were deleted, and two termination 
codons and a bel-1 splice donor site mutation were introduced into these vectors 
(Schmidt et al., 1995). The vector pFOV-7, containing the herpes virus type 1 (HSV-1) 
thymidine kinase (tk), the E.coli cytosine deaminase (cd) and the polynucleotide 
phosphorylase (pnp) genes, was introduced into tumor cells and promoted their death 
(Nestler et al., 1997).  
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Fig. 2. The development of HFV vectors. The replication-competent FV vectors were deleted 
noncoding sequences in bel-2 and bel-3. The non-replicating FV vectors were constructed by 
the portion of the env gene replaced by marker gene. The bel-1-independent FV vector 
system contains relevant packaging plasmid and the vector plasmid carrying exogenous 
gene. The adenovirus and human foamy virus hybrid vector system express separately the 
HFV structural genes gag and pol, the HFV structural gene env, and the transgene. 
3.2 Non-replicating HFV 
The second generation FV vectors were non-replicating HFV, lacking portions of the 
structure gene. The recombinant foamy virus vectors (pFGPSN and pFGPMAP) were 
constructed by replacing a portion of the env gene with the neomycin phosphotransferase 
gene under the control of the SV40 early promoter and the human placental alkaline 
phosphatase gene under the control of the MLV LTR promoter, respectively (David & 
Russell, 1996). These vectors were capable of transducing diverse cells (David & Russell, 
1996), including human fibroblasts, COS-7 cells, Vero cells, Cf2Th cells, etc. Furthermore, 
these vectors transduced cells from different species, including steer, sheep, dog, cat, rat and 
hamster and at different stages of the cell cycle, thus suggesting that HFV could transduce 
dividing and non-dividing cells. 
3.3 Bel-1-independent HFV 
The third generation FV vectors were Bel-1-independent HFV. This foamy virus vector 
system contained relevant packaging plasmid (pCGPES) and vector plasmids 
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(pCGPMAPDBel and pCGPMscvF) (Vassilopoulos et al., 2001). In this vector, a constitutive 
CMV/HFV fusion promoter derived from the cytomegalovirus (CMV) promoter replaced 
the HFV LTR U3 region sequences (Trobridge & Russell, 1998). The gag, pol, and env were 
placed under control of an SV40 polyadenylation site (SV pA) in the packaging plasmid 
pCPGES, and the reporter gene, AP or GFP, was expressed respectively by internal MLV 
LTR or murine stem cell virus (MSCV) promoters (Vassilopoulos et al., 2001). Thus, the gag 
and pol genes were not expressed in transduced cells after reverse transcription. Researchers 
demonstrated that the 5’ portion of gag and 3’ portion of pol were critical for viral product 
(Heinkelein et al., 1998; Erlwein et al., 1998). Thus, it may be possible for foamy virus vectors 
to contain fewer viral sequences in the future. 
3.4 Human foamy virus hybrid vector 
To improve the viral titer, adenovirus and human foamy virus hybrid vector systems 
(pFAD-2 and pFAD-7) were developed (Picard-Maureau et al., 2004). An infectious 
extracellular particle could be produced by pFAD-2 containing the PFV gene. The pFAD-7 
lacked the PFV env gene required for viral capsid export and could therefore only undergo 
an intracellular replication cycle. Both of these FV vectors were controlled by the 
tetracycline-regulatable system. The other adenoviral/PFV hybrid vector was generated 
from three different adenoviruses and achieved gene transfer in vitro (Russell et al., 2004). 
These vectors separately expressed the PFV structural genes gag and pol (Ad-GagPolDPacI), 
the PFV structural gene env (Ad-Env), and the transgene (Ad-MD9). After co-transduction 
by the three adenoviruses, release of recombinant PFV was generated, and a titer of up to 
103 vector particles/ml was achieved. 
It has been shown that these hybrid vectors can effectively improve the titer and integrate 
into host genome. Additional foamy virus hybrid vectors have been developed, and more 
research needs to be undertaken to verify their effectiveness and safety.  
3.5 FVs derived from other species 
In addition to the prototypic PFV (Trobridge et al., 1998; Heinkelein et al., 1998; Trobridge et 
al., 2002; Schmidt et al., 1995; Nestler et al., 1997; Heinkelein et al., 2002), a variety of FV 
vectors have been developed, including simian foamy virus type 1 (SFV-1, macaque) (Wu et 
al., 1998; Park et al., 2002) and feline foamy virus (FFV) (Bastone et al., 2006; Bastone et al., 
2007). A series of vectors and helper plasmids derived from SFV-1 have been constructed, 
and the minimum vector sequence required for efficient gene transduction has been 
established. This minimum vector contained the 5’ untranslated region to the first 637 
nucleotides of the gag, 596 nucleotides of pol, while the 3’ LTR removed 1131 nucleotides. 
Therefore, with different packaging plasmids and helper plasmids, this vector can carry an 
8930 base-size heterologous DNA fragment.  
4. The advantages of FV 
Research groups have designed a novel type of vehicle based on FVs for use as gene 
delivery vectors. FVs are classified in the subfamily Spumaretroviridae (Khan et al., 2009). 
FVs have been reported to be prepotent in relation to other retroviral subfamilies, such as 
HIV and HTLV, in terms of safety and efficiency. FVs have many advantages that allow 
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them to transduce target cells for treating nervous system disorders. The advantages of 
functional gene transfer vectors derived from foamy viruses are as follows. 
a. FVs have a wide range of hosts and can infect a variety of tissues and cells (Heneine et 
al., 1998; Russell & Miller, 1996). They were first found in mammalian species, while 
humans can be infected through occupational and non-occupational exposure to 
infected animals and their tissues, blood or body fluids (Khan et al., 2009). The feature 
of a broad host tropism makes FVs suitable for wide use in gene therapy.  
b. Most retroviral vectors derived from FVs are nonpathogenic to humans (Caprariello et 
al., 2009). There is not enough evidence indicating the ability of foamy viruses to be 
transmitted between populations (Liu et al., 2005; Mergia et al., 2001). Furthermore, 
long-term studies of animal care workers and experimental researchers infected by 
foamy viruses have failed to show negative consequences (Mergia et al., 2001; Saib et 
al., 1997). Thus, there is little or no risk of developing malignancies in patients treated 
with gene therapy by FV vectors.  
c. The size of the foamy virus genome is the largest amongst all retroviruses (Flugel et al., 
1991; Trobridge et al., 2002). Thus, it is able to transport large fragments of foreign 
genetic material into cells. As therapeutic genes can be too large to be delivered by 
common retroviral vectors, the ability of FV vectors to package foreign genes is 
significant. FVs can be used as gene therapy vectors for the diseases that are caused by 
the loss of large fragments of functional genes.  
d. FVs possess a dual-promoter, which makes them unique. Whereas all retroviruses have 
a promoter in their U3 region of the long terminal repeat sequence, FVs have an internal 
promoter that is located at the end of the env (Liu et al., 2005; Lochelt et al., 1993). The 
two promoters co-regulate the expression of therapeutic genes at both temporal and 
spatial levels in target cells. 
e. FVs have a distinct integration pattern compared with other retroviral vectors. Bauer et 
al. have studied these patterns, and unlike gammaretroviral and lentiviral vectors, there 
seems to be an inverse correlation between gene density and integration frequency. 
Furthermore, FV vectors integrated significantly fewer times near oncogenes, as 
demonstrated using integration-site and statistical analysis (Bauer et al., 2008). The 
unique integration pattern indicates that FVs prefer inserting into non-transcribed areas 
of the chromosome, which promotes the development of FV vectors in gene therapy. 
f. Recently, researchers have found that the number of integration sites in a cell gradually 
increased over several weeks following viral infection. Most of the additional 
integration sites appeared in regions of low gene density (Bauer et al., 2008). This may 
be, to some extent, why FV vectors are safer and have a higher expression as well as 
long-term efficacy.  
g. FVs particles are simple and convenient to obtain for basic medical research and clinical 
trials. FVs are stable enough to be concentrated by ultracentrifugation and maintain the 
ability to introduce and express genes in target cells (Josephson et al., 2004). 
These unique characteristics of FVs make them suitable to be used as foreign gene delivery 
systems in treating genetic diseases, especially nervous disorders. However, low viral titer 
limits the application of FV vectors to clinical treatments. Furthermore, it is uncertain 
whether a mutation could occur after integration, which would be a serious threat to the 
health and survival of individuals undergoing gene therapy treatment.  
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5. Transduction of neural and other cells by FV vectors 
5.1 Transduction of a variety of cells derived from diverse species 
FV vectors can transduce diverse human cells (David & Russell, 1996), including human 
fibroblasts, 293 cells and COS-7 cells. FV vectors can also transduce cells derived from other 
species, such as, Vero and Cf2Th cells. These cells can be transduced by FV vectors at 
different stages (M phase or stationary phase) of the cell cycle (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. The cell model transduced by FVs. Infectious viral particles enter cells and 
concentrate around the centrosomes. Under the help of centrosomes, the PIC enter the 
nucleus. After integration, the viral genes are expressed, and the viral proteins are 
synthesized. The viral particles are assembled in internal membranes, and released by 
budding. 
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5.2 Transduction of growth-arrested cells 
Research has demonstrated that FV vectors can transduce MRC5 cells and human fibroblasts 
that have been arrested using aphidicolin (G1/S phase) (Saib et al., 1997; Trobridge et al., 
2004), although the integration pattern (integration or non-integration) remains unclear. 
5.3 Transduction of neural cells and brain tissues 
NT2.N neurons, a postmitotic human neuronal cell line, can be transduced by simian foamy 
virus-1 (SFV-1) vectors (Mergia et al., 2001). Neural cells, cultured astrocytes, cultured rat 
hippocampal and dorsal root ganglia neurons are also transducible by FV vectors (Liu et al., 
2005; Liu et al., 2007; Liu et al., 2008). Brain tissues can be transduced by FV vectors in a rat 
model (Caprariello et al., 2009). 
6. Possible mechanisms for the transduction of neural cells and other 
growth-arrested cells 
Although the underlying mechanism of foamy viral transduction in neural and nondividing 
cell is unclear, some clues can be acquired from the unique life cycle of FVs (Figure 3). 
The viral structure of foamy viruses is special. FVs possess two coordinated promoters (Liu 
et al., 2005; Lochelt et al., 1993): one is located in the U3 region of the LTR, while the other, 
termed IP, is located at the end of the env gene. With the largest genome among all 
retroviruses (11,021 bp), FV vectors can carry a large transgene cassette (9.2 kb) (Flugel et al., 
1991; Trobridge et al., 2002.) 
Foamy viral reverse transcription, integration, transcription and packaging processes are 
also distinct. The reverse transcription during viral particle formation produces 20% of viral 
particles containing the full-length viral cDNA genome (Mergia et al., 2001), which is 
conducive to the formation of the PIC. The Tas (transactivator of spumavirus) plays a critical 
role in foamy viral replication and transcription. The pol gene of FVs is directly spliced from 
the mRNA, which is unique to FVs (Yu et al., 1996; Enssle et al., 1996). Therefore, the 
protease reverse-transcriptase-integrase proteins, derived from the Pol, are activated early 
and may facilitate the formation of the preintegration complex (PIC). As an element of the 
PIC, the Gag protein is cleaved into a mature product near the C-terminus. The entrance of 
the PIC into the nucleus utilizes the centrioles. The frequency of foamy viral integration is 
inversely correlated with gene density, with foamy virus preferring to integrate into regions 
of low gene density (Bauer et al., 2008). 
7. Application of FV vectors in neurological disorders and other diseases 
It has been reported that 2 of 11 children who received gene therapy developed leukemia 
due to the use of retroviral vectors, which may lead to the insertional activation of 
nearby oncogenes (Marshall, 2002; Marshall, 2003). In contrast, foamy virus is a safe and 
promising vector system for gene transfer into various cell types, including neurocytes. 
The potential applications of FV vectors for gene therapy are summarized below and in 
Table 1. 
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Virus Diseases Transgenes References 
HFV Parkinson’s disease GAD gene Liu et al. 2007 
HFV Neuropathic pain GAD gene Liu et al. 2008 
FV 
Lukocyte adhesion 
deficiency 
MSCV- CD18 Bauer et al. 2008 
FV 
Lukocyte adhesion 
deficiency 
PGK-CD18 Bauer et al. 2011 
PFV 
Gioblastoma xenograft 
model 
FOV-7/pnp,  
FOV-7/ntr,  
FOV-7/tk suicide 
gene 
Heinkelein et al. 2005 
HFV Cancer Interleukin-24 Chen et al. 2010 
HFV HIV infection Interferon-tau Fujii et al.2004 
SFV-1 SIV infection R2 siRNA Park et al. 2005 
FV HIV infection 
RevM10, Sh1 and 
maC46 
Taylor et al.2008 
HFV Hpatitis B siRNA Sun et al. 2007 
FV 
Cronic granulomatous 
disease 
gp91phox 
Chatziandreou et al. 
2011 
Table 1. Foamy Virus Vectors used in Neurological Disorders and other diseases 
7.1 Parkinson’s disease 
Parkinson’s disease (PD) is the second most common age-related progressive 
neurodegenerative disorder (Feng et al., 2010). Currently, the treatment of PD is focused on the 
amelioration of symptoms and does not have a satisfactory therapeutic effect. Caprariello and 
colleagues demonstrated that high-titer FV, which is able to efficiently transduce brain 
parenchyma, had the potential for gene therapy of disorders of the central nervous system 
(CNS) (Caprariello et al., 2009). FV-vector-mediated gene transfer to neural progenitor cells 
that are potential vehicles for delivery of therapeutic agents into the brain can achieve 
differentiation-dependent gene expression (Rothenaigner et al., 2009). In a rat model of PD, 
replication-defective HFV vectors were used to transduce astrocytes, which were then injected 
into the subthalamic nucleus (STN) region of PD animal models. The HFV vector-derived 
glutamic acid decarboxylase (GAD) expression in the astrocytes resulted in behavioral 
recovery of the rats. The transduction of the GAD vector achieved isoform-specific expression 
of GAD, synthesis of a significant amount of gamma-aminobutyric acid (GABA) and the 
release of tonically active GABA (Liu et al., 2007). GABA is primarily synthesized from 
glutamate (glutamic acid) by the pyridoxal-5-phosphate-dependent glutamic acid 
decarboxylase. GAD65 and GAD67 are two isoforms of GAD in the brain, which provide a 
dual system for the control of neuronal GABA (Figure 4). GAD65 is mainly present as an 
inactive apoenzyme and can be induced by nerve activity, whereas GAD67 is a pyridoxal 
phosphate-bound permanently active holoenzyme (Lindefors, 1993). In this study, replication-
defective vector (rdv) GAD67 or rdvGAD65 were injected into the rat STN. There was a 
significant decrease in the rotation rates of the rdvGAD65 rats while the rdvGAD67 rats did 
not. This study demonstrates that HFV vector-derived GAD expression in astrocytes provides 
a potential approach to repair GABA transmission in neurological disorders (Liu et al., 2007). 
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Fig. 4. GABA is primarily synthesized from glutamate (glutamic acid) by GAD67 and 
GAD65. GAD67, which might preferentially synthesize cytoplasmic GABA, appears to be 
distributed more uniformly in neurons. GAD65, which might preferentially synthesize 
GABA for vesicular release, tends to be concentrated in nerve terminals. In most 
physiological circumstances, GABA-uptake transporters rapidly remove GABA that is 
released from the synapse into the extracellular space. However, the GABA transporter can 
reverse its action and release GABA from neurons or glial cells under certain conditions. FV 
vectors encoding GAD65 or GAD67 can achieve significant synthesis and release of GABA, 
which may ameliorate neurological disorders associated with hyperexcitable or diminished 
inhibitory activity. 
7.2 Neuropathic pain 
Neuropathic pain is an important health concern that is often refractory to medical 
management. Further studies of neuropathic pain have made the development of gene 
therapy a possibility. Subcutaneous inoculation of a replication-defective HFV vector 
expressing GAD67 attenuated below-injury level central neuropathic pain after spinal cord 
injury (SCI). To achieve the release of GABA, the GAD67 gene was transferred into dorsal 
root ganglion (DRG) cells for 7 days after T13 spinal cord hemisection. The result suggests 
that HFV-mediated gene transfer to DRG could be applied to treat below-injury level central 
neuropathic pain after incomplete SCI (Liu et al., 2008). The inhibitory effect of GABA, 
which is the major inhibitory neurotransmitter in the mammalian central nervous system, is 
mediated by GABAA, GABAB and GABAC/GABAA-ρ receptors (Rissman et al., 2011). 
GABA-mediated depolarization influences the excitability of sensory neurons both in cell 
www.intechopen.com
Development of Foamy Virus Vectors for  
Gene Therapy for Neurological Disorders and Other Diseases 
 
91 
bodies and nerve terminals by inactivating other voltage-sensitive channels, such as Ca2+ 
and Na+. It is also possible that the GABA-activated a Cl- current directly that inhibits an 
ATP-evoked excitatory current in DRG neurons (Naik et al., 2008).  
7.3 Leukocyte adhesion deficiency 
Gene transfer into hematopoietic stem cells (HSCs) is a promising treatment approach for 
many hematologic and genetic diseases. FV vectors can overcome safety concerns and the 
low HSC transduction rates found with oncoretroviral vectors. Recombinant FV vectors 
efficiently transduced human umbilical cord blood CD34+ cells that were injected into 
nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice (Leurs et al., 
2003; Josephson et al., 2002; Josephson et al., 2004; Zucali et al., 2002). The transduced 
human cells expressed high levels of the transgene in lymphoid, myeloid, and progenitor 
cells (Leurs et al., 2003; Vassilopoulos et al., 2001; Josephson et al., 2002). Additionally, there 
was no transgene silencing (Vassilopoulos et al., 2001; Josephson et al., 2002). Compared 
with FV, human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors 
pseudotyped with gibbon ape leukemia virus envelope (GALV Env) and murine leukemia 
virus (MLV)-based oncoretroviral vectors were inefficient in transducing NOD/SCID 
repopulating cells (Leurs et al., 2003). Bauer et al. demonstrated that FV vectors expressing 
the canine CD18 gene from an internal murine stem cell virus (MSCV) promoter could 
correct the lymphocyte proliferation and neutrophil adhesion defects characteristic of canine 
leukocyte adhesion deficiency (LAD). This work was the first successful use of FV vectors to 
treat a genetic immunodeficient disease. In addition, genotoxic complications were not 
observed, and compared with gammaretroviral vectors, integration site analysis revealed a 
polyclonality of transduced cells and a decreased risk of integration near oncogenes (Bauer 
et al., 2008). In another study, an FV vector expressing canine CD18 from a 
phosphoglycerate kinase (PGK) gene promoter, without an enhancer that would activate 
neighboring genes, expressed CD18 efficiently in canine neutrophils and CD34+ cells. 
However, dogs continued to suffer from LAD after treatment of hematopoietic stem cells 
transduced with the PGK-CD18 vector. This suggests that the PGK promoter cannot 
effectively replace the MSCV promoter in CD18-expressing FV vectors and that a strong 
promoter-enhancer may be necessary in FV vectors for the treatment of human LAD (Bauer 
et al., 2011). 
7.4 Cancer 
Selective introduction of a foreign gene into tumor cells to produce an enzyme is the basis of 
suicide gene therapy as an anticancer strategy. The gene product activates an inert prodrug to 
its cytotoxic form, which results in tumor cell death (Bhaumik, 2011). To evaluate the effect of 
tumor growth suppression utilizing suicide gene therapy, FV vectors expressing the purine 
nucleoside phosphorylase (FOV-7/pnp), the nitroreductase (FOV-7/ntr), or the thymidine 
kinase (FOV-7/tk) suicide genes were injected into the nude-mouse/human subcutaneous 
U87 glioblastoma xenograft model. Mice with vector virus-injected tumors were treated with 
the respective prodrug, resulting in a significant inhibition of tumor growth. Without prodrug 
treatment, a similar suppression of tumor growth was also observed both in mice with vector 
virus-injected U87 tumor cells and in the G59 glioma model that received the FOV-7/pnp 
virus vector. Furthermore, wild-type FV, instead of the suicide gene-transducing vectors, was 
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able to inhibit tumor growth, suggesting an oncolytic activity of foamy virus replication in a 
nude-mouse glioblastoma xenograft tumor model. However, the vector is not restricted to the 
tumor and persists in various mouse tissues. This persistence limits its potential use in clinical 
trials (Heinkelein et al., 2005). Replication-defective HFV vectors expressing interleukin-24 also 
exhibited an inhibitory effect on cancer cells (Chen et al., 2010). 
7.5 Acquired immunodeficiency syndrome 
FV vectors have the potential for gene therapy of acquired immunodeficiency syndrome in 
patients who are resistant to traditional antiviral therapy. The nonpathogenic HFV mediated 
intracellular expression of ovine interferon-tau permitted cells to be resistant to HIV 
infection (Fujii et al., 2004). Vectors developed from SFV expressing anti-rev/env (R2) short-
interfering RNA (siRNA) effectively inhibited simian immunodeficiency virus (SIV) 
replication. This result shows that R2 siRNA reduces the rev and env gene expression and is 
a potent inhibitor of SIV replication (Park et al., 2005). Taylor and co-workers used three 
anti-HIV transgenes, including a dominant negative version of the viral rev protein 
(RevM10), a short hairpin RNA directed against a conserved overlapping sequence of the tat 
and rev genes (Sh1), and a membrane-attached peptide blocking HIV cell entry (maC46). 
These transgenes, expressed by foamy virus vectors both individually and collectively, were 
used to determine if they were able to effectively block HIV replication in macrophages. 
HIV replication was specifically blocked by maC46 or sh1 transgene expression. Entry 
inhibition by the maC46 transgene was the most effective method of blocking HIV 
replication among these three individual transgenes. In addition, the three anti-HIV 
transgenes expressed by FV vectors together effectively blocked HIV infection in primary 
macrophages derived from transduced, peripheral blood CD34-selected cells and in a cell 
line used for propagating HIV (Taylor et al., 2008).  
7.6 Hepatitis B Virus (HBV) 
Double-stranded RNA initiates and directs sequence-specific, post-transcriptional silencing 
of homologous genes. The use of RNA interference (RNAi), which is mediated by double-
stranded small interfering RNA (siRNA), has received attention for the treatment of 
infectious diseases caused by viral or parasitic infection (Arenz et al., 2003). To successfully 
apply RNAi in the treatment of HBV infection, it was necessary to screen specific RNAi 
targeting sequences that could effectively knock down HBV transcripts. In a cell-based HBV 
infection model, two effective siRNA sequences designated S2 and X1 were cloned into 
HFV-based vectors to produce single siRNA expression vectors (HFVU6-siS2, HFVU6-siX1) 
and a dual siRNA expression vector (HFVU6-siSX). These siRNA vectors achieved long-
term inhibition of HBV gene expression and viral DNA replication. HFVU6-siSX 
simultaneously expressing the two siRNAs that targeted the S and X genes of HBV was the 
most potent inhibitor of HBV replication, suggesting HFVU6-siS2 and HFVU6-siX1 may 
cooperate to inhibit HBV mRNA expression (Sun et al., 2007). 
7.7 Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is a fatal genetic defect in leukocyte function caused 
by mutations in any of the four genes encoding the subunits (p22phox, gp91phox, p47phox and 
www.intechopen.com
Development of Foamy Virus Vectors for  
Gene Therapy for Neurological Disorders and Other Diseases 
 
93 
p67phox) of phagocyte NADPH oxidase (Kume et al., 2000; Chatziandreou et al., 2011). The 
majority of CGD cases are due to sex-linked recessive inheritance resulting from mutations 
in the CYBB gene encoding gp91phox. Chatziandreou et al. evaluated the gene transfer 
potential of FV vectors in an X-linked form of chronic granulomatous disease (X-CGD). FV 
vectors expressing the human codon-optimized gp91phox reconstituted NADPH activity in 
vitro in the X-CGD cell line, ex vivo in primary murine HSCs and in vivo in the X-CGD 
mouse model of the disease. Sustained long-term expression of the gp91phox transgene and a 
high percentage of superoxide-producing cells in the peripheral blood of transplanted X-
CGD mice was achieved by FV vectors, suggesting that FV-based vectors were effective 
therapeutic vehicles for the genetic correction of X-CGD (Chatziandreou et al., 2011). 
8. Perspectives 
Because foamy virus infections are nonpathogenic, FVs have been considered potential 
vectors for the advancement of gene therapy. Moreover, the discovery of the internal 
promoter, IP, and the transactivator, Tas, have greatly promoted the research on foamy 
viruses. However, new issues have arisen in the course of foamy virus research; for 
example, studies have mainly focused on the primate foamy virus, which limits the field. 
Additionally, the products and functions of the structural and regulatory genes are not 
completely understood. Furthermore, although FVs are widespread, the host cell receptors 
are not yet known. These unknown features make the development of foamy virus gene 
therapy vectors difficult, yet there is still an interest in their development.  
The use of viral mediated gene transfer is challenged by serious defects, yet they remain a 
potential tool of gene therapy for various diseases (Bastone et al., 2007). Therefore, it is 
critical to find a refined vector that is efficient and safe for treatment of the diseases, 
especially for nervous system therapy. To date, it is believed that FVs are nonpathogenic to 
the host, and their regulation of gene expression has been widely studied. Foamy virus is a 
widespread retrovirus with a unique structure that is innocuous in both human and primate 
infections. Thus, compared with the four major viral vector systems, the FV vectors appear 
to be a harmless and capable vehicle. With the increased understanding of neurological 
diseases and the improvement of gene therapy, the potential future of FV-based vectors 
carrying therapeutic genes for nervous systems and other organic systems is bright. 
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